Project Grant HT94252310121

This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to uncover the mechanism underlying hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) transcriptional silencing in individuals with HBV mono-infection and HBV/HIV co-infection. The $2,279,005 award, effective from July 2024 through May 2029, will enable researchers at The Johns Hopkins...

This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...

This federal Project Grant award of $234,735.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the immune mechanisms that influence hepatitis B virus (HBV) clearance. The key objectives are to: 1) Examine the role of co-stimulatory signaling pathways in the age-dependent capacity of hepatic conventional dendritic cells to activate CD4+ T cells, and...

This $814,790 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to uncover the immune mechanisms underlying the clearance of hepatitis B virus (HBV) surface antigen (HBsAg) in chronic HBV patients. The research is being conducted by a team of investigators at the University of California, San Francisco (UCSF), with the goal of advancing the understanding of HBsAg...

This is a Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), totaling $2,225,199 and effective from July 1, 2024 to May 31, 2029. The primary objective is to identify the key immune correlates and mechanisms underlying functional cure of hepatitis B virus (HBV) infection. The research will define the roles of HBV-specific CD4 T cells and B cells in viral control and pathogenesis,...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is providing $510,306 to Emory University to support research into virus-host interactions that could lead to a cure for chronic hepatitis B virus (HBV) infections. The project aims to advance understanding of the mechanisms by which HBV genotypes and mutations affect disease progression and response to interferon-alpha...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $598,764 to The Trustees of Princeton University to conduct research on targeting the hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) during HBV/HIV co-infection. The research aims to determine whether liver-specific genetic disruption of host factors involved in cccDNA formation can abrogate HBV...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to discover a safe and effective long-acting antiviral therapy for hepatitis B (HBV) that can provide sustained viral suppression. The $762,072 grant will fund a 5-year translational research project to leverage expertise and collaborative capacity to transform current short-acting oral antiviral drugs into a long-acting...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $483,194 to the Research Institute at Nationwide Children's Hospital (RINCH) to define the protective CD4+ T cell responses against the hepatitis C virus (HCV). The research aims to characterize the CD4+ T cell signatures that support effective CD8+ T cell immunity against HCV, using historical blood and...

This $2,357,206 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop an immunocompetent mouse model susceptible to hepatitis B virus (HBV) infection. The goal is to identify host and viral factors that can overcome the species barrier and enable HBV infection and persistence in murine hepatocytes. Key objectives include determining if genetic diversity...